Chesapeake Asset Management’s Definium Therapeutics DFTX Stock Holding History

Chesapeake Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.55K	Hold	33	–	–	﹤0.01%	348
2026 Q1	$623	Hold	33	–	–	﹤0.01%	317
2025 Q4	$441	Hold	33	–	–	﹤0.01%	343
2025 Q3	$389	Hold	33	–	–	﹤0.01%	305
2025 Q2	$214	Hold	33	–	–	﹤0.01%	312
2025 Q1	$193	Hold	33	–	–	﹤0.01%	520
2024 Q4	$229	Hold	33	–	–	﹤0.01%	479
2024 Q3	$187	Hold	33	–	–	﹤0.01%	493
2024 Q2	$237	Hold	33	–	–	﹤0.01%	323
2024 Q1	$310	Hold	33	–	–	﹤0.01%	305
2023 Q4	$120	Hold	33	–	–	﹤0.01%	371
2023 Q3	$103	Hold	33	–	–	﹤0.01%	421
2023 Q2	$117	Hold	33	–	–	﹤0.01%	409
2023 Q1	$104	Buy	+33	New	+$110	﹤0.01%	405

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Chesapeake Asset Management's DFTX Position: Q2 2026 in Review

Chesapeake Asset Management held its Definium Therapeutics (DFTX) position steady in Q2 2026 at 33 shares worth $1.55K. The position accounts for ﹤0.01% of the portfolio, ranked #348.

Chesapeake Asset Management first reported a position in DFTX in Q1 2023 and has held it in 14 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Chesapeake Asset Management held 33 shares of Definium Therapeutics worth $1.55K as of Q2 2026.
Chesapeake Asset Management left its Definium Therapeutics share count unchanged in Q2 2026.
Definium Therapeutics made up ﹤0.01% of Chesapeake Asset Management's portfolio in Q2 2026, its #348 holding.
Chesapeake Asset Management first reported a position in Definium Therapeutics in Q1 2023 and has held it in 14 quarters since.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Chesapeake Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.